ATE477811T1 - Oxytocin zur behandlung von autismus und asperger-syndrom - Google Patents

Oxytocin zur behandlung von autismus und asperger-syndrom

Info

Publication number: ATE477811T1
Authority: AT; Austria
Prior art keywords: oxytocin; autism; analogs; methods; asperger
Prior art date: 2002-10-03

Application number

AT03770645T

Other languages

English (en)

Inventor

Eric Hollander

Original Assignee

Neuropharmacology Services Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-03

Filing date

2003-10-03

Publication date

2010-09-15

2003-10-03 Application filed by Neuropharmacology Services Llc filed Critical Neuropharmacology Services Llc

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE477811T1 publication Critical patent/ATE477811T1/de

Links

XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title abstract 7
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title abstract 4
101800000989 Oxytocin Proteins 0.000 title abstract 4
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title abstract 4
229960001723 oxytocin Drugs 0.000 title abstract 4
206010003805 Autism Diseases 0.000 title abstract 3
208000020706 Autistic disease Diseases 0.000 title abstract 3
208000036640 Asperger disease Diseases 0.000 title 1
201000006062 Asperger syndrome Diseases 0.000 title 1
230000003542 behavioural effect Effects 0.000 abstract 2
230000006735 deficit Effects 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
230000003989 repetitive behavior Effects 0.000 abstract 2
208000013406 repetitive behavior Diseases 0.000 abstract 2
230000006399 behavior Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
238000011260 co-administration Methods 0.000 abstract 1
230000007278 cognition impairment Effects 0.000 abstract 1
230000001149 cognitive effect Effects 0.000 abstract 1
230000002939 deleterious effect Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000001003 psychopharmacologic effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT03770645T 2002-10-03 2003-10-03 Oxytocin zur behandlung von autismus und asperger-syndrom ATE477811T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41583702P	2002-10-03	2002-10-03
PCT/US2003/031493 WO2004030524A2 (en)	2002-10-03	2003-10-03	Treatment of autism and similar disorders

Publications (1)

Publication Number	Publication Date
ATE477811T1 true ATE477811T1 (de)	2010-09-15

Family

ID=32069910

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03770645T ATE477811T1 (de)	2002-10-03	2003-10-03	Oxytocin zur behandlung von autismus und asperger-syndrom

Country Status (9)

Country	Link
US (1)	US9662371B2 (de)
EP (1)	EP1556068B1 (de)
CN (1)	CN1711101A (de)
AT (1)	ATE477811T1 (de)
AU (2)	AU2003279137A1 (de)
CA (1)	CA2500831A1 (de)
DE (1)	DE60333857D1 (de)
ES (1)	ES2353690T3 (de)
WO (1)	WO2004030524A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1556068B1 (de)	2002-10-03	2010-08-18	Neuropharmacology Services, LLC	Oxytocin zur Behandlung von Autismus und Asperger-Syndrom
US7884076B2 (en) *	2003-11-06	2011-02-08	The Trustees Of Columbia University In The City Of New York	Multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders
JO2937B1 (en)	2004-08-11	2016-03-15	فيرينغ.بي.في	Tight muscles of the peptide vascular tensioner receptor
HRP20130719T1 (en)	2005-08-24	2013-09-30	Eisai R&D Management Co., Ltd.	Novel pyridine derivative and pyrimidine derivative (3)
RU2415149C2 (ru)	2006-02-10	2011-03-27	Ферринг Б.В.	Пептидные соединения
CA2661333C (en)	2006-08-23	2014-08-05	Eisai R&D Management Co., Ltd.	Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
WO2008059991A1 (en)	2006-11-15	2008-05-22	National University Corporation Kanazawa University	Diagnosis and treatment of autism using cd38
WO2009037586A2 (en)	2007-08-14	2009-03-26	Ferring B.V.	Use of peptidic vasopressin receptor agonists
JP2009132660A (ja)	2007-11-30	2009-06-18	Eisai R & D Management Co Ltd	食道癌治療用組成物
WO2011027060A2 (fr)	2009-09-04	2011-03-10	Centre National De La Recherche Scientifique - Crns -	Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
EP2485744A4 (de) *	2009-10-09	2014-01-22	Prothera Inc	Zusammensetzungen und verfahren mit pediokokken zur reduzierung mindestens eines symptoms für autismusspektrumserkrankungen bei einem patienten mit diagnostizierter autismusspektrumserkrankung
US20130058915A1 (en)	2010-03-02	2013-03-07	Children's Medica Center Corporation	Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20130130985A1 (en) *	2010-04-01	2013-05-23	Paul Alewood	Oxytocin peptide analogues
WO2011146726A1 (en) *	2010-05-19	2011-11-24	The University Of North Carolina At Chapel Hill	Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders
US20120108510A1 (en)	2010-05-20	2012-05-03	Emory University	Methods of improving behavioral therapies
JO3400B1 (ar)	2010-09-30	2019-10-20	Ferring Bv	مركب صيدلاني من كاربيتوسين
CN106924259A (zh)	2012-08-06	2017-07-07	S1制药有限公司	治疗方案
JP6304744B2 (ja) *	2013-12-20	2018-04-04	国立大学法人福井大学	愛着障害治療剤
SG11201705591PA (en)	2015-01-07	2017-08-30	Trigemina Inc	Magnesium-containing oxytocin formulations and methods of use
KR101815348B1 (ko) *	2015-05-06	2018-01-08	인제대학교 산학협력단	폭식성 섭식장애 조절을 위한 옥시토신의 용도
HUE070412T2 (hu) *	2016-04-12	2025-06-28	Tonix Pharma Ltd	Magnézium tartalmú oxitocin készítmények és alkamazási eljárásaik
SMT202300283T1 (it)	2016-04-15	2023-11-13	Baylor College Medicine	Lactobacillus reuteri mm4-1a per l’uso nel trattamento o nella prevenzione dei disturbi dello spettro autistico
WO2022073008A1 (en) *	2020-09-30	2022-04-07	Baylor College Of Medicine	Oxytocin treatment for hypermobile ehlers-danlos syndrome
CN117320566A (zh) *	2020-12-30	2023-12-29	通用医疗公司	用于治疗自闭症谱系障碍的方法和组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4229880A1 (de) *	1992-09-04	1994-03-31	Knauf Siegfried	Medikament bzw. Medikamentenzusammensetzung
EP1006798A4 (de) *	1996-09-05	2003-03-05	Massachusetts Inst Technology	Zusammensetzungen und verfahren zur behandlung neurologischer störungen und neurodegenerativer erkrankungen
SE9701161D0 (sv) *	1997-03-27	1997-03-27	Karolinska Innovations Ab	New use I
AU4869399A (en)	1998-07-10	2000-02-01	Curagen Corporation	Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon)
US6894026B1 (en) *	2000-01-11	2005-05-17	Atossa Healthcare, Inc.	Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20070032410A1 (en) *	2000-01-11	2007-02-08	Atossa Healthcare, Inc.	Compositions and methods for the treatment of psychiatric disorders
FR2807038B1 (fr) *	2000-04-03	2002-08-16	Sanofi Synthelabo	Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
US6673790B1 (en) *	2000-04-03	2004-01-06	Sanofi-Synthelabo	Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
WO2001076629A1 (en)	2000-04-07	2001-10-18	Takeda Chemical Industries, Ltd.	Soluble beta amyloid precursor protein secretion promoters
AU2001256350A1 (en)	2000-05-12	2001-11-20	Bayer Aktiengesellschaft	Regulation of human lysostaphin-like protease
EP1556068B1 (de)	2002-10-03	2010-08-18	Neuropharmacology Services, LLC	Oxytocin zur Behandlung von Autismus und Asperger-Syndrom
US20030166600A1 (en) *	2002-11-20	2003-09-04	Shyam Ramakrishnan	Regulation of human isotocin-like g protein-coupled receptor

2003
- 2003-10-03 EP EP03770645A patent/EP1556068B1/de not_active Expired - Lifetime
- 2003-10-03 WO PCT/US2003/031493 patent/WO2004030524A2/en not_active Ceased
- 2003-10-03 CA CA002500831A patent/CA2500831A1/en not_active Abandoned
- 2003-10-03 AT AT03770645T patent/ATE477811T1/de not_active IP Right Cessation
- 2003-10-03 AU AU2003279137A patent/AU2003279137A1/en not_active Abandoned
- 2003-10-03 ES ES03770645T patent/ES2353690T3/es not_active Expired - Lifetime
- 2003-10-03 US US10/530,246 patent/US9662371B2/en not_active Expired - Fee Related
- 2003-10-03 CN CNA2003801029806A patent/CN1711101A/zh active Pending
- 2003-10-03 DE DE60333857T patent/DE60333857D1/de not_active Expired - Lifetime
2009
- 2009-05-25 AU AU2009202043A patent/AU2009202043A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60333857D1 (de)	2010-09-30
ES2353690T3 (es)	2011-03-04
EP1556068A2 (de)	2005-07-27
US9662371B2 (en)	2017-05-30
WO2004030524A2 (en)	2004-04-15
CA2500831A1 (en)	2004-04-15
EP1556068A4 (de)	2008-01-02
EP1556068B1 (de)	2010-08-18
AU2009202043A1 (en)	2009-06-18
WO2004030524A3 (en)	2004-06-10
CN1711101A (zh)	2005-12-21
AU2003279137A1 (en)	2004-04-23
US20060105939A1 (en)	2006-05-18

Legal Events

Date	Code	Title	Description
2011-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE477811T1 (de)	2010-09-15	Oxytocin zur behandlung von autismus und asperger-syndrom
ATE399553T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE410157T1 (de)	2008-10-15	Modafinil enthaltende zusammensetzung zur behandlung von aufmerksamkeitsdefizitsyndrom/hyperaktivität
ATE510542T1 (de)	2011-06-15	Noribogain zur behandlung von schmerzen und drogenabhängigkeit
ATE328588T1 (de)	2006-06-15	Behandlung von nicotinsucht und sucht bedingtem verhalten
ATE552837T1 (de)	2012-04-15	Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen
DE60237158D1 (de)	2010-09-09	Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
DE60019106D1 (de)	2005-05-04	Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
DE60008143D1 (de)	2004-03-11	Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
TW200511996A (en)	2005-04-01	The use of steroids to treat persons suffering from ocular disorders
ATE499933T1 (de)	2011-03-15	Verwendung von betain zur behandlung von claudicatio intermittens
ATE222768T1 (de)	2002-09-15	Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
Lion et al.	1970	Group psychotherapy with violent outpatients
GARDNER et al.	1949	Interruption of the Sympathetic Nerve Supply to the Brain—Effect on Parkinson's Syndrome
BR0317772A (pt)	2005-11-22	Método de tratamento de um distúrbio de comportamento, uso de um composto, e, agente terapêutico para um distúrbio de comportamento
ATE407925T1 (de)	2008-09-15	1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
Haque et al.	2020	Effects of Various Factors on Maxillary Arch Dimensions in Unilateral Cleft Lip and Palate Children: A Multi-population Study
ATE418558T1 (de)	2009-01-15	Darstellung von 1-aza-2-oxadibenzoäe,hüazulenen und deren verwendung bei der herstellung pharmazeutischer formulierungen zur behandlung und prävention von krankheiten und erkrankungen des zentralen nervensystems
DE60224078D1 (de)	2008-01-24	Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
Pawar	2017	Binaural Beats and Background Music For Increased Focus and Relaxation
DE60126504D1 (de)	2007-03-22	Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa